Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 3/20 | 0.42 |
| ▸ | ELANE | P08246 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | NQO2 | P16083 | 1/20 | 0.34 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29875049 | 1.00 | PARP1 (0.42) | PARP1ELANEACHEMEN1KMT2A | |
| SCHEMBL7811084 | 0.81 | PARP1 (0.46) | PARP1ELANEACHE | |
| SCHEMBL31140889 | 0.81 | PARP1 (0.46) | PARP1ELANEACHE | |
| SCHEMBL28626526 | 0.81 | ACHE (0.44) | PARP1ELANEACHE | |
| SCHEMBL2712792 | 0.76 | BCHE (0.32) | ACHE | |
| SCHEMBL31607526 | 0.76 | ELANE (0.44) | PARP1ELANEACHENQO2 | |
| SCHEMBL1563528 | 0.76 | ELANE (0.44) | PARP1ELANEACHENQO2 | |
| SCHEMBL7692120 | 0.76 | PDPK1 (0.47) | PARP1ELANEACHENQO2 | |
| SCHEMBL26215545 | 0.76 | BACE1 (0.38) | ELANE | |
| SCHEMBL26731037 | 0.73 | ALDH1A1 (0.32) | MEN1KMT2ANQO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12404249-B2 | Heterocyclic derivatives and use thereof | C&C RESEARCH LABORATORIES (KR) | 2025-09-02 | — | — | US | disclosed |
| EP-3802495-B1 | 4-(2-((2-CHLOROQUINOLIN-4-YL)AMINO)ETHYL)BENZENESULFONAMIDE DERIVATIVES AS STAT3 INHIBITORS FOR THE TREATMENT OF CANCER | C&C RES LAB (KR) | 2025-07-02 | — | — | EP | disclosed |
| CN-112204010-B | Heterocyclic derivatives and uses thereof | C&C新药研究所 | 2024-03-19 | — | — | CN | disclosed |
| US-20220388962-A1 | MOLECULES THAT BIND TO TDP-43 FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS AND RELATED DISORDERS | FOX CHASE CHEMICAL DIVERSITY CENTER INC. | 2022-12-08 | — | — | US | disclosed |
| EP-4017492-A1 | MOLECULES THAT BIND TO TDP-43 FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS AND RELATED DISORDERS | Biohaven Therapeutics Ltd. (US) | 2022-06-29 | — | — | EP | disclosed |
| CN-114667145-A | Molecules that bind to TDP-43 for the treatment of amyotrophic lateral sclerosis and related disorders | 拜尔哈文制药股份有限公司 | 2022-06-24 | — | — | CN | disclosed |
| US-20210155594-A1 | HETEROCYCLIC DERIVATIVES AND USE THEREOF | C&C RESEARCH LABORATORIES (KR) | 2021-05-27 | — | — | US | disclosed |
| EP-3802495-A1 | HETEROCYCLIC DERIVATIVES AND USE THEREOF | C&C Research Laboratories (KR) | 2021-04-14 | — | — | EP | disclosed |
| WO-2021035101-A1 | MOLECULES THAT BIND TO TDP-43 FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS AND RELATED DISORDERS | BIOHAVEN THERAPEUTICS LTD. (US) | 2021-02-25 | — | — | WO | disclosed |
| CN-112204010-A | Heterocyclic derivatives and use thereof | C&C新药研究所 | 2021-01-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220388962-A1 | MOLECULES THAT BIND TO TDP-43 FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS AND RELATED DISORDERS | TARDBP, TDP1, TDP2 | PARP1 743/4885ELANE 1988/4885ACHE 2466/4885 |
| US-20210155594-A1 | HETEROCYCLIC DERIVATIVES AND USE THEREOF | STAT3, JAK2, IRF3 | PARP1 438/4885ELANE 1818/4885ACHE 4845/4885 |
| US-12404249-B2 | Heterocyclic derivatives and use thereof | STAT3, JAK2, IRF3 | PARP1 438/4885ELANE 1818/4885ACHE 4845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.